The emerging deep science animal health and nutrition company is gathering investors to secure Series B funding for the next wave of innovation in microbial animal solutions
SAN DIEGO – (BUSINESS WIRE) – May 27, 2020 –
The animal health and nutrition industry is evolving and the tools for improving animal health and nutrition are growing Ascus Biosciences.
Ascus uses its proprietary technology platform to solve the complexity in the native microbial communities that live in highly productive and healthy animals. Effective native microorganisms are selected from these curated findings, isolated from animal samples and developed into products. These new products with multiple strains and naturally occurring whole microbes are storage-stabilized and compatible with standard feed systems for animal feed. This method is the first of its kind in the animal health and nutrition industry, where most microbial products on the market are not developed based on a thorough understanding of animal microbiomes.
The financing was managed by a global investment company Temasekwith the participation of other leading investors, Anterra Capital, Formation 8 and Cavallo Ventures (the venture capital arm of Wilbur Ellis) and additional support from various angel investors.
"Animals make up an increasing part of our economy and food supply, but the majority of feed additives available are at least 50 years old," said Jim Kim, founder and general partner of Formation 8. "Using modern science as a means to better understand animal health and nutrition is both better for global food supply and in line with animal welfare. "
With $ 46 million raised as part of the Series B fundraiser, Ascus is well positioned to continue expanding its customer sales and service teams, developing new and existing products in its product pipeline, and refining its core technology platform and intellectual property foundation.
"By securing this level of funding, farmers and pet owners can use Ascus technology to search for newer, safer, and more effective microbial solutions on a much larger scale as we continue to expand our sales and customer service footprint in the United States and around the world," said Michael Seely , CEO of Ascus Biosciences. "With this round of financing, we are now well positioned to expand and serve our existing and potential customers as we continue to develop the breakthrough products currently in our research and development pipeline."
Ascus has several microbial solutions under development, some of which are already in sales mode, from dairy products, poultry, beef, horses to companion types.
About Ascus Biosciences
Ascus is headquartered in San Diego and has multiple field, sales and manufacturing operations worldwide. visit AscusBiosciences.com to learn more about the technology and science behind these innovative products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005624/de/
Michelle Fluty
OBP
michelle.fluty@obpagency.com
309-261-7247
The information
Ascus Biosciences
info@AscusBiosciences.com
